A Phase 1/2 Two-Stage Dose Escalation and Randomized Parallel-Group Study to Evaluate the Safety, Preliminary Treatment Effects, and Durability of AR-14034 Sustained Release Implant Compared to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment in Participants with Neovascular Age-Related Macular Degeneration
Latest Information Update: 16 Apr 2025
At a glance
- Drugs Aflibercept (Primary) ; Axitinib (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms NOVA-1
- Sponsors Aerie Pharmaceuticals
Most Recent Events
- 10 Apr 2025 Planned End Date changed from 1 Mar 2027 to 1 Apr 2027.
- 10 Apr 2025 Planned primary completion date changed from 1 Mar 2027 to 1 Apr 2027.
- 28 May 2024 Planned End Date changed from 1 Feb 2027 to 1 Mar 2027.